Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
By S. Cannistra, U. Matulonis, R. Penson, J. Hambleton, J. Dupont, H. Mackey, J. Douglas, R. Burger, D. Armstrong, R. Wenham and 1 more. Journal of Clinical Oncology, 2007
795 citations recorded by the source corpus.
Subfields: Molecular Biology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/784e6950ddaa3b6fd3e0e4a0b8a3015b428e5cd5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Reproductive Medicine
In Surgery
Citations in the corpus
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. (2014, background): “Strict exclusion criteria were implemented to reduce the risk of GI perforation, which was previously reported at a high incidence in patients receiving bevacizumab for heavily pretreated ovarian cancer.(11) We report the efficacy and safety results from AURELIA.”
- A phase 3 trial of bevacizumab in ovarian cancer. (2011, neutral): “Any thromboembolic event None 708 (94) 665 (89) Grade 1 or 2 22 (3) 29 (4) Grade ≥3 23 (3) 51 (7) Venous thromboembolic event None 722 (96) 695 (93) Grade 1 or 2 18 (2) 18 (2) Grade ≥3 13 (2) 32 (4) Arterial thromboembolic event None 742 (99) 718 (96) Grade 1 or 2 1 (<1) 7 (1) Grade ≥3 10 (1) 20 (3)”
- OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. (2011, methodology): “A third study evaluated BV alone in 44 patients with platinum-refractory or platinumresistant disease (two to three prior regimens and progression during or within 3 months of treatment with topotecan or pegylated liposomal doxorubicin).(9) This study showed an ORR of 15.”
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, result): “Patients demonstrated a response rate of 16%; however, the trial closed early due to an unexpectedly high incidence of GI perforation in 5 of 44 patients (11%).(112) A subsequent review of the available literature suggested that the incidence of GI perforation in ovarian cancer patients treated with”